Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Other Operating Expenses (2017 - 2024)

Avalo Therapeutics' Other Operating Expenses history spans 7 years, with the latest figure at $87000.0 for Q4 2024.

  • For Q4 2024, Other Operating Expenses fell 97.64% year-over-year to $87000.0; the TTM value through Sep 2025 reached $87000.0, down 99.72%, while the annual FY2024 figure was $27.3 million, 425.43% up from the prior year.
  • Other Operating Expenses reached $87000.0 in Q4 2024 per AVTX's latest filing, up from -$714000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $27.5 million in Q1 2024 to a low of -$714000.0 in Q3 2024.
  • Average Other Operating Expenses over 4 years is $2.5 million, with a median of $655500.0 recorded in 2021.
  • The largest YoY upside for Other Operating Expenses was 4883.3% in 2024 against a maximum downside of 389.07% in 2024.
  • A 4-year view of Other Operating Expenses shows it stood at $691000.0 in 2021, then dropped by 10.27% to $620000.0 in 2022, then soared by 494.52% to $3.7 million in 2023, then tumbled by 97.64% to $87000.0 in 2024.
  • Per Business Quant, the three most recent readings for AVTX's Other Operating Expenses are $87000.0 (Q4 2024), -$714000.0 (Q3 2024), and $446000.0 (Q2 2024).